Effect of tocainide on ventricular arrhythmias refractory to standard oral antiarrhythmic drugs but responsive to intravenous lidocaine

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty patients with life-threatening or symptomatic ventricular arrhythmias which were not responsive to standard oral antiarrhythmic drugs either because of lack of efficacy or because of adverse effects but which were responsive to intravenous lidocaine were subjects. The dose of tocainide was individually titrated for each patient according to efficacy and adverse effects. The mean daily tocainide dose was 1800 mg (range 1200-2400 mg). Three of 20 patients (15%) died of their underlying heart disease - one during the acute tocainide study and two during long-term tocainide treatment. Adverse effects from tocainide occurred in 11 of 20 patients (55%) and six (30%) had to discontinue tocainide because of major adverse effects - four during the acute tocainide study and two during long-term tocainide treatment. Fifteen patients on long-term tocainide were followed for a mean of 12 months (range 1-30 months). In the 13 patients able to tolerate long-term tocainide alone or in combination with other antiarrhythmic drugs, ventricular fibrillation occurred in none of four patients with prior ventricular fibrillation, short runs of ventricular tachycardia occurred in four of 11 patients (36%) with prior recurrent ventricular tachycardia, and couplets of PVCs occurred in eight of 12 patients (67%) with prior couplets. We conlcude that, in this selected group of patients at high-risk for sudden death, tocainide alone or in combination with other antiarrhythmic drugs prevented deterioration of life-threatening ventricular arrhythmias.

Original languageEnglish
Pages (from-to)272-278
Number of pages7
JournalCurrent Therapeutic Research - Clinical and Experimental
Volume33
Issue number2
StatePublished - 1983

Fingerprint

Tocainide
Anti-Arrhythmia Agents
Lidocaine
Cardiac Arrhythmias
Ventricular Fibrillation
Ventricular Tachycardia
Sudden Death
Polyvinyl Chloride

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{80516e5000fb405593618772cf7e018e,
title = "Effect of tocainide on ventricular arrhythmias refractory to standard oral antiarrhythmic drugs but responsive to intravenous lidocaine",
abstract = "Twenty patients with life-threatening or symptomatic ventricular arrhythmias which were not responsive to standard oral antiarrhythmic drugs either because of lack of efficacy or because of adverse effects but which were responsive to intravenous lidocaine were subjects. The dose of tocainide was individually titrated for each patient according to efficacy and adverse effects. The mean daily tocainide dose was 1800 mg (range 1200-2400 mg). Three of 20 patients (15{\%}) died of their underlying heart disease - one during the acute tocainide study and two during long-term tocainide treatment. Adverse effects from tocainide occurred in 11 of 20 patients (55{\%}) and six (30{\%}) had to discontinue tocainide because of major adverse effects - four during the acute tocainide study and two during long-term tocainide treatment. Fifteen patients on long-term tocainide were followed for a mean of 12 months (range 1-30 months). In the 13 patients able to tolerate long-term tocainide alone or in combination with other antiarrhythmic drugs, ventricular fibrillation occurred in none of four patients with prior ventricular fibrillation, short runs of ventricular tachycardia occurred in four of 11 patients (36{\%}) with prior recurrent ventricular tachycardia, and couplets of PVCs occurred in eight of 12 patients (67{\%}) with prior couplets. We conlcude that, in this selected group of patients at high-risk for sudden death, tocainide alone or in combination with other antiarrhythmic drugs prevented deterioration of life-threatening ventricular arrhythmias.",
author = "Esterbrooks, {Dennis J.} and Aronow, {W. S.} and Mohiuddin, {Syed M.}",
year = "1983",
language = "English",
volume = "33",
pages = "272--278",
journal = "Current Therapeutic Research",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - Effect of tocainide on ventricular arrhythmias refractory to standard oral antiarrhythmic drugs but responsive to intravenous lidocaine

AU - Esterbrooks, Dennis J.

AU - Aronow, W. S.

AU - Mohiuddin, Syed M.

PY - 1983

Y1 - 1983

N2 - Twenty patients with life-threatening or symptomatic ventricular arrhythmias which were not responsive to standard oral antiarrhythmic drugs either because of lack of efficacy or because of adverse effects but which were responsive to intravenous lidocaine were subjects. The dose of tocainide was individually titrated for each patient according to efficacy and adverse effects. The mean daily tocainide dose was 1800 mg (range 1200-2400 mg). Three of 20 patients (15%) died of their underlying heart disease - one during the acute tocainide study and two during long-term tocainide treatment. Adverse effects from tocainide occurred in 11 of 20 patients (55%) and six (30%) had to discontinue tocainide because of major adverse effects - four during the acute tocainide study and two during long-term tocainide treatment. Fifteen patients on long-term tocainide were followed for a mean of 12 months (range 1-30 months). In the 13 patients able to tolerate long-term tocainide alone or in combination with other antiarrhythmic drugs, ventricular fibrillation occurred in none of four patients with prior ventricular fibrillation, short runs of ventricular tachycardia occurred in four of 11 patients (36%) with prior recurrent ventricular tachycardia, and couplets of PVCs occurred in eight of 12 patients (67%) with prior couplets. We conlcude that, in this selected group of patients at high-risk for sudden death, tocainide alone or in combination with other antiarrhythmic drugs prevented deterioration of life-threatening ventricular arrhythmias.

AB - Twenty patients with life-threatening or symptomatic ventricular arrhythmias which were not responsive to standard oral antiarrhythmic drugs either because of lack of efficacy or because of adverse effects but which were responsive to intravenous lidocaine were subjects. The dose of tocainide was individually titrated for each patient according to efficacy and adverse effects. The mean daily tocainide dose was 1800 mg (range 1200-2400 mg). Three of 20 patients (15%) died of their underlying heart disease - one during the acute tocainide study and two during long-term tocainide treatment. Adverse effects from tocainide occurred in 11 of 20 patients (55%) and six (30%) had to discontinue tocainide because of major adverse effects - four during the acute tocainide study and two during long-term tocainide treatment. Fifteen patients on long-term tocainide were followed for a mean of 12 months (range 1-30 months). In the 13 patients able to tolerate long-term tocainide alone or in combination with other antiarrhythmic drugs, ventricular fibrillation occurred in none of four patients with prior ventricular fibrillation, short runs of ventricular tachycardia occurred in four of 11 patients (36%) with prior recurrent ventricular tachycardia, and couplets of PVCs occurred in eight of 12 patients (67%) with prior couplets. We conlcude that, in this selected group of patients at high-risk for sudden death, tocainide alone or in combination with other antiarrhythmic drugs prevented deterioration of life-threatening ventricular arrhythmias.

UR - http://www.scopus.com/inward/record.url?scp=0020657333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020657333&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 272

EP - 278

JO - Current Therapeutic Research

JF - Current Therapeutic Research

SN - 0011-393X

IS - 2

ER -